Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 in mCRC with Acquired Resistance to Anti-EGFR mAbs
NCT02965417Phase 2Withdrawn
- Sponsor
- Symphogen
- Start
- Dec 2016
- Primary completion
- Jan 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of futuximab + modotuximab in colorectal cancer (metastatic) (mCRC), sponsored by Symphogen. Planned start Dec 2016; status: withdrawn.
02
Drugs
futuximab + modotuximab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02965417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965417.